Genocea Biosciences, Inc.

Genocea harnesses the power of T cells to discover life-changing vaccines and immunotherapies. While traditional discovery methods have largely used in silico methods to propose T cell targets, or antigens, we use ATLASTM, our proprietary technology platform, to identify clinically relevant T cell antigens based on patients’ own T cell immune responses to their cancers. We are using ATLAS’s superiority in antigen identification to develop neoantigen cancer vaccines with our lead candidate, GEN-009, expected to enter clinical development in early 2018.

Bank Name Genocea Biosciences, Inc.
Stock Exchange NASDAQ
Symbol GNCA
Sector Healthcare
Industry Biotechnology: Biological Products
Country United States
World Region America
CEO Mr. William D. Clark M.B.A.
Employees 52
Registered Year 2006